Content Type: Article

  • Practical Insurance Advice in the Wake of COVID-19

    Practical Insurance Advice in the Wake of COVID-19

    ARTICLE / CLIENT ALERT

    Practical Insurance Advice in the Wake of COVID-19

    April 1, 2020

    Read time: 6 min

    Key takeaways
    Overview

    In a prior Alert, we reported on the New York State Department of Financial Services (“NYDFS”) directive to insurers, requiring that they provide their policyholders with an explanation of how their commercial property and business interruption insurance policies will apply to losses resulting from COVID-19. We have had the opportunity to review a number of responses from the insurers. As expected, many of the insurers did not specifically address each policyholder individually, but rather forwarded general position papers to their policyholders and the NYDFS. See Chubb’s response as an example.

    The insurers’ typical response with respect to commercial property coverage is to refer the policyholder back to the policy terms. Insurers also emphasize that coverage applies only where there is physical loss or damage to property caused by a covered peril, but do not discuss under what circumstances, if any, COVID-19 would trigger the coverage. The insurers also raise other coverage issues — for example, Chubb’s notice to policyholders indicates that policy exclusions may apply to COVID-19 claims.

    With respect to business interruption (“BI”) insurance, the insurers have offered a more detailed and nuanced discussion. The insurers again emphasize that the policy generally applies only where there is physical loss or damage from a covered peril. In addition, the insurers add that, in the absence of a communicable disease coverage endorsement, an infectious agent or disease alleged to have resulted in loss will generally not be considered to have caused physical loss or damage. According to the insurers, physical loss or damage means something physical or structural, or that the property has been altered by a covered peril. We have not seen any insurer response that directly addresses coverage for BI losses as a result of a civil authority restricting access to a covered premise.

    Based on what has been published and discussed, it appears inevitable that courts will be called upon to decide the key question — whether a virus present in the environment — that results in a pandemic — that causes a civil authority to limit access to premises — resulting in business interruption losses — qualifies as physical damage within the meaning of commercial property insurance policies? The insurers’ preliminary positions and their responses to NYDFS make clear that insurers intend to assert that, absent an infectious disease coverage endorsement, the presence of COVID-19 does not constitute physical loss or damage.

    Courts have come to different conclusions with respect to what the policy term “physical loss or damage” means. Some courts have required measurable physical or tangible change or alteration of the property, other courts have reasoned that physical loss or damage does not necessarily have to be something that can be seen or touched, finding that odors constitute physical loss.

    Review Your Management Liability and Property Insurance

    Losses resulting from COVID-19 could potentially implicate insurance under numerous types of policies including commercial property, management liability, employment practices liability, workers’ compensation, event cancellation and travel insurance policies. For most businesses and fund managers, commercial property insurance and management liability policies will be the most important.

    We must caution that any discussion of insurance coverage and policy interpretation defies broad generalities and is dependent on the terms of the specific policies at issue. Policyholders are advised to consult an insurance professional or counsel for assistance involving policy evaluation and interpretation.

    Checklist for Fund Managers and Financial Professionals

    • Do you have a management liability policy? Many investment managers have a suite of coverages under the umbrella of investment management insurance. The coverage typically includes director & officers’ (“D&O”), errors & omissions, (“E&O”) and employment practices liability (“EPL”).
      • D&O policies are designed to provide protection for directors, officers and managers as well as the insured entities and general partners and members against allegations of wrongful acts, errors, omissions or a breach of fiduciary duty. This could include coverage for third-party claims against insureds for mismanagement of the portfolio through the pandemic and resulting market turbulence. D&O policies may have broad bodily injury exclusions.
      • E&O policies are intended to cover the investment advisor, the general partners and members against claims alleging wrongful acts, errors, omissions, misstatements, misleading statements, negligence or breach of duty with regard to professional services and advice given to third parties. In the current business climate, such services and advice could give rise to third-party claims alleging negligence associated with the pandemic.
      • EPL is written to provide an employer with protections against allegations of workplace discrimination, harassment or wrongful termination. Under present circumstances, should an employee be dismissed and allege wrongful dismissal related to the pandemic, EPL coverage could be implicated.
    • Do you have property and BI insurance?
      • Is your policy “All Risk” or “Named/Covered Peril”?
        • If your policy is All Risk, it requires the insurer to exclude specific perils.
      • Does your insurance require physical loss or damage?
        • Some policies have non-physical damage or loss extensions.
      • Is there coverage for BI losses resulting from the order of a civil authority?
        • Is access to your premises prohibited?
        • Is there a physical loss or damage requirement tied to BI losses?
      • Is your policy endorsed to provide infectious disease coverage?
      • Does your policy have an infectious disease exclusion?
      • Is your business contingent on support from third parties who cannot or are prohibited from operating?
      • Does your policy provide for disruption in your supply chain?

    Notice of Circumstances

    • Policyholders should consider giving notice of circumstances.
    • Recent publications have suggested that insurers are considering adding broad infectious disease and pandemic exclusionary provisions to policies at renewal.
    • A notice of circumstances may preserve a policyholder’s rights under its existing insurance policies.

    Recent Legislative Developments

    • Legislators in certain states, including New York and Massachusetts, have introduced bills that, if passed, would require that BI insurance (for businesses with less than 100 employees) cover losses arising from COVID-19. New Jersey had previously considered such legislation but the bill has reportedly been withdrawn.
    • Under these proposed bills, COVID-19 losses would be covered for the duration of a declared state of emergency subject to policy limits.

    Authored by Howard B. Epstein and Theodore A. Keyes.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Howard B. Epstein

    Of Counsel

    New York – 919 Third Avenue

    Theodore A. Keyes

    Partner

    New York – 919 Third Avenue

    More insights

  • Paycheck Protection Program Loans to Small Businesses — Treasury Issues Application Form and Additional Guidance

    Paycheck Protection Program Loans to Small Businesses — Treasury Issues Application Form and Additional Guidance

    ARTICLE / CLIENT ALERT

    Paycheck Protection Program Loans to Small Businesses — Treasury Issues Application Form and Additional Guidance

    April 1, 2020

    Read time: 8 min

    Key takeaways
    Overview

    On March 31, 2020, the U.S. Department of the Treasury (“Treasury”) issued additional guidance to small businesses seeking loans under the Paycheck Protection Program (“Program”) of the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). As discussed in our prior SRZ Alert, this Program allocated $349 billion in government-backed forgivable loans (“Loan(s)”) to small businesses.

    The Treasury expects the Small Business Administration (“SBA”) to have the Program up and running by April 3, 2020, with Loan applications to be made available to small businesses and sole proprietorships at that time. Loan applications will be made available to independent contractors and self-employed individuals on April 10, 2020. A copy of the application form for Loans under the Program was published by the Treasury and is available here. Once the Program is implemented, small businesses can apply for a Loan directly through an existing SBA-certified lender or federally insured depository institution, federally insured credit union or Farm Credit System institution that participates in the Program.[1]

    This Alert highlights additional information for small businesses seeking Loans. For a more detailed description of the Program (as well as certain other relief applicable to small businesses under the CARES Act), please see our prior Alert and the Treasury’s CARES Act page.

    Loan Terms

    The Treasury announced that all Loans will have the following identical features: (i) fixed interest rate of 0.50%; (ii) maturity of 2 years; (iii) payments deferred for six months (although interest will accrue during this time); (iv) 100% guaranteed by the SBA; (v) no collateral requirement; (vi) no personal guarantee requirement; and (vii) no borrower or lender fees payable to the SBA.

    As indicated in our prior Alert, the full principal amount of the Loan will be forgiven as long as (i) the Loan proceeds are used to cover payroll costs, most mortgage interest, rent and utility costs over the eight-week period after the Loan is originated; and (ii) certain employee and compensation levels are maintained. However, due to the likely high demand for Loans, the Treasury anticipates that not more than 25% of the forgiven amount may be used for non-payroll costs.

    Under the Program, borrowers will need to complete and submit a Loan application (see below) with the required documentation to an approved lender that can process their application by June 30, 2020. Although the Program is open until July 30, 2020, borrowers are encouraged to apply as soon an possible, as there is a funding cap and it will take time for lenders to process the high volume of applications that are expected.

    Lenders and Agents

    All existing SBA-certified lenders will be given delegated authority to process Loans. All federally insured depository institutions, federally insured credit unions and Farm Credit System institutions are also eligible to participate in the Program, as are certain[2] nonbank lenders. Prospective lenders will need to submit an application to DelegatedAuthority@sba.gov, and can begin making Loans as soon as they are approved and enrolled in the Program.

    As discussed in our prior Alert, lenders will be compensated by processing fees, which will be based on the balance of the financing outstanding at the time of final[3] disbursement as follows: (i) 5.00% for Loans up to $350,000; (ii) 3.00% for Loans greater than $350,000 to $2 million; and (iii) 1.00% for Loans greater than $2 million.[4] Lenders may not collect any fees from the Loan applicant. Loans issued under the Program may be sold in the secondary market; the SBA will not collect fees from such sales.

    Lenders will, however, have to pay any agent fees out of such processing fees. Agent fees are as follows: (i) 1.00% for Loans up to $350,000; (ii) 0.50% for Loans greater than $350,000 to $2 million; (iii) 0.25% for Loans greater than $2 million. An agent is an authorized representative and can be any of the following: attorney; accountant; consultant; someone who prepares an applicant’s application for financial assistance and is employed and compensated by the applicant; someone who assists a lender with originating, disbursing, servicing, liquidating or litigating SBA loans; a loan broker; or any other individual or entity representing an applicant by conducting business with the SBA. Agents also may not collect fees from a Loan applicant.

    The SBA will guarantee 100% of the outstanding balance of all Loans and will waive all SBA guaranty fees, including both the upfront and annual service fees. For underwriting purposes, lenders will need to (i) verify that a borrower was in operation on Feb. 15, 2020; (ii) verify that a borrower had employees for whom the borrower paid salaries and payroll taxes; (iii) verify the dollar amount of average monthly payroll costs; and (iv) follow applicable Bank Secrecy Act requirements.

    Loan Application

    The application form to obtain a Loan is relatively short and straightforward. Besides administrative information concerning the business (e.g., name, address, taxpayer identification or employer identification number, etc.), the application will require potential borrowers to set forth (i) a dollar amount reflecting its average monthly payroll expenses for 2019, excluding costs over $100,000 on an annualized basis for each employee[5]; (ii) the number of jobs it employs; (iii) the purpose(s) for the Loan; and (iv) information with respect to any owner having a 20% or greater ownership interest (each, an “Owner”).

    The application also contains a series of questions that will bar an applicant for obtaining a Loan, including, whether the business or any Owner (i) is presently suspended, debarred or proposed for debarment by any federal department or agency; (ii) is presently involved in any bankruptcy; (iii) has defaulted on a Federal or SBA loan in the last seven years and caused a loss to the government; and (iv) is presently subject to formal criminal charges, or has been in the past seven years subject to certain judgments for a felony or misdemeanor for a crime against a minor. The business and each Owner must also answer if they own any other business or have common management with any other business, and if so, attach a list of such affiliates and describe the relationship. Additional information on eligibility requirements can be found in our prior Alert. Notably, a potential borrower must also represent that it will purchase only American-made equipment and products, to the extent feasible.

    As mentioned in our prior Alert, Potential borrowers, including each Owner, must certify that (i) due to current economic uncertainty, the Loan request is “necessary” to support continued operations; and (ii) Loan proceeds will be used to maintain a workforce and payroll or to make mortgage, lease or utility payments.[6] The application form additionally requires potential borrowers to certify, among other things, that (i) documentation evidencing such payments will be provided for the first eight weeks of the Loan; (ii) it acknowledges that due to the anticipated high volume of Loan applicants, only 25% of the forgiven amount may be used for non-payroll costs; (iii) it does not have another Loan application pending and has not received funds for the same purpose; and (iv) it acknowledges that knowingly making a false statement to obtain a Loan is punishable by imprisonment and/or a fine.

    Authored by Stuart D. Freedman, Andrew J. Fadale, Ian L. Levin, David J. Passey, Joseph P. Vitale, David M. Rothenberg, Adam J. Barazani and Travis Gantt.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] The SBA and Treasury are authorized to extend authority to other lenders so long as such lenders have the necessary qualifications to process, close, disburse and service the Loans.

    [2] The Treasury guidance does not provide any details on what criteria will be used to evaluate prospective nonbank lenders, whom the statute indicates must have the “necessary qualifications to process, close, disburse and service [Loans].” H.R. 748 §11 02(a)(1)(F)(iii).

    [3] Interestingly, the Treasury guidance adds the word “final,” which does not appear in the CARES Act, thereby suggesting that disbursement may not occur all at once.

    [4] Interestingly, while the Treasury guidance indicates a loan in the amount of $2 million would be subject to a 3% processing fee, under the CARES Act such a Loan would appear to be subject to a 1% fee.

    [5] For seasonal businesses, the Loan applicant may elect to instead use average monthly payroll for the time period between Feb. 15, 2019 and June 30, 2019, excluding costs over $100,000 on an annualized basis for each employee. For new businesses, average monthly payroll may be calculated using the time period from Jan. 1, 2020 to Feb. 29, 2020, excluding costs over $100,000 on an annualized basis for each employee.

    [6] If the Loan proceeds are used for an unauthorized purpose, the federal government may pursue criminal fraud charges.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Ian L. Levin

    Partner

    New York – 919 Third Avenue

    Adam J. Barazani

    Partner

    New York – 919 Third Avenue

    More insights

  • CMS Issues Broad Package of Blanket Waivers Under Section 1135

    CMS Issues Broad Package of Blanket Waivers Under Section 1135

    ARTICLE / CLIENT ALERT

    CMS Issues Broad Package of Blanket Waivers Under Section 1135

    March 31, 2020

    Read time: 7 min

    Key takeaways
    Overview

    The updated waivers build upon the more limited set of Section 1135 waivers issued on March 13, 2020, and address common concerns among Medicare providers and suppliers as they deal with the Coronavirus (COVID-19) pandemic. The waivers are effective retroactive to March 1, 2020.

    In depth

    Late on March 30, 2020, the Centers for Medicare and Medicaid Services (CMS) issued a broad package of blanket regulatory waivers, as permitted under Section 1135 and other provisions of the Social Security Act, applicable to certain providers and suppliers (updated waivers). The updated waivers build upon a more limited set of Section 1135 waivers issued on March 13, 2020 (analyzed here), and include waivers applicable to many Medicare provider and suppliers. The waivers are effective retroactive to March 1, 2020.

    General Themes

    The updated waivers address common concerns among providers and suppliers across the country, including waivers in cases where a provider is part of a “surge” or acting as a “surge facility” or “surge site.” Providers should review both the specific fact sheet guidance for their provider or supplier type(s) (discussed below), along with the consolidated summary of the updated waivers to review the scope of the waivers provided by CMS.

    Important Process Changes

    CMS clarified that providers and suppliers need not provide written notice of intent to operate under blanket waivers, including the updated waivers. Providers and suppliers that have identified the need for additional waiver relief under Section 1135 based on their specific facts and circumstances in relation to the Coronavirus (COVID-19) pandemic may still apply for “case-by-case” waivers over and above those provided in the updated waivers. However, requests for case-by-case waivers outside the scope of the updated waivers or previously granted waivers should be requested by emailing 1135waiver@cms.hhs.gov rather than emailing the provider’s CMS Regional Office as indicated by prior guidance.

    While CMS has issued blanket Stark Law waivers, requests for additional Stark Law waivers should be sent to 1877CallCenter@cms.hhs.gov.

    Examples of Provider Types and Features of the Updated Waivers

    Hospitals (defined for these purposes as general acute care, psychiatric and critical access hospitals) may, among other actions permitted by the prior waivers and the updated waivers:

    • Screen patients at locations offsite from the hospital’s campus to prevent spread of COVID-19, so long as consistent with the state emergency preparedness or pandemic plans (collectively, state plans)
    • Use non-hospital buildings/space for patient care and quarantine sites, so long as approved by the provider’s state and not inconsistent with the state plans
    • Waive certain requirements under the Medicare conditions of participation (CoPs) and the provider-based department requirements to allow hospitals to establish and operate as part of the hospital any location meeting those CoPs that continue to apply during the emergency
    • More liberally utilize verbal orders
    • Not report all deaths of patients in restraints
    • Disregard certain provisions of the patient rights COP in circumstances where the hospital is located in a state “impacted by a widespread outbreak of COVID-19,” which currently means 51 or more confirmed cases (which is already the case in many states)
    • Re-use face masks in sterile compounding areas, so long as certain requirements are met
    • Adapt discharge planning processes to reduce the burden on caregivers
    • Continue medical staff privileges where the privileges expire or provide new privileges prior to a full medical staff and governing body review, to assist with workforce concerns
    • Relax requirements for medical records department staffing, the form and content of the record and record retention requirements, so long as in compliance with state plans
    • Function under relaxed telemedicine requirements
    • Rely upon non-physician providers to provide and oversee care to patients, so long as permitted by state plans
    • Relax requirements for QAPI programs
    • Relieve the requirement for preparing and updating nursing care plans and maintaining certain outpatient policies and procedures regarding nursing coverage.

    For critical access hospitals, the waivers also include relief related to personnel qualifications, staff licensure, critical access hospital status and location, and length of stay.

    Long term care and skilled nursing facilities (SNFs) may, among other actions permitted by the updated waivers:

    • Postpone Minimum Data Set reporting and submission of staffing data
    • Suspend pre-admission screening and annual resident review assessments for a limited time
    • Use non-SNF buildings as temporarily certified facilities available for use by a SNF should isolation be necessary for COVID-19-positive residents that cannot be provided in the current physical space
    • Coordinate with the state to open a new nursing facility if the state determines such a temporary isolation and treatment location is necessary
    • Modify nurses’ aide training and certification requirements for a limited time period
    • Permit telehealth visits in lieu of in-person physician visits
    • Disregard resident roommate choice provisions in favor of grouping or cohorting residents with respiratory symptoms or confirmed COVID-19 separate from asymptomatic or COVID-19-negative residents
    •  Facilitate certain resident transfers based on COVID-19 status to help isolate infectious residents and temporarily observe potentially infected residents for the identified incubation period, provided certain requirements are met.

    Home health agencies may, among other actions permitted by the updated waivers:

    • Extend timeframes for certain OASIS transmissions
    • Undertake initial assessments and determination of homebound status remotely or by record review
    • Temporarily disregard the requirement for certain onsite nursing visits for HHA supervision.

    Hospice providers may, among other actions permitted by the updated waivers:

    • Extend the timeframe for completion of certain comprehensive assessments
    • Disregard the requirement to provide non-core services such as PT, OT and speech/language pathology services
    • Temporarily disregard the requirement for certain onsite nursing visits for hospice aide supervision.

    Relevant to other provider types, CMS simultaneously issued additional fact sheets specific to:

    • Durable medical equipment, prosthetics, orthotics and supplies (DMEPOS)
    • Physicians and other practitioners
    • Ambulances
    • End stage renal dialysis (ESRD) facilities
    • Teaching hospitals and medical residency programs
    • Inpatient rehabilitation facilities
    • LTACHs and cancer hospitals
    • Rural health clinics and FQHCs
    • Laboratories covid-long-term-care-hospitals.pdf
    • Diabetes prevention programs
    • Medicare Advantage and Part D plans.

    Additional Medicare Enrollment Flexibilities

    The updated waivers build upon prior enrollment waivers and flexibilities (analyzed here) and include:

    • Permitting Part A certified providers and suppliers establishing isolation facilities to call the Medicare Administrative Contractor hotlines to enroll and receive temporary Medicare billing privileges
    • Allowing physicians and other practitioners to render telehealth services from their home without reporting their home address on their Medicare enrollment while continuing to bill from their currently enrolled location.
    • Allowing opted-out physicians and non-physician practitioners to terminate their opt-out status early and enroll in Medicare to provide care to more patients.

    Open Issues

    To date, CMS has primarily provided guidance on COVID-19 flexibility through sub-regulatory guidance documents with limited operational details, and has frequently updated its guidance as circumstances evolve. While it appears that CMS is committed to being responsive to the needs of providers and the public, the specific legal authority supporting many of the flexibilities that are being provided outside of the scope of the Section 1135 waiver authority remains unclear.

    Providers should consult with counsel before operating under the waiver provisions to ensure that the services being provided fall within the scope of the waiver. Further, providers operating under the waivers are advised to regularly monitor CMS websites for changes to the scope of waived provisions and information regarding operational and documentation requirements that may be imposed at a later date

    Key Takeaways: The updated waivers provide additional regulatory relief as providers and suppliers continue to address the operational challenges presented by the COVID-19 pandemic. Tracking the current scope of the waivers, understanding what is not waived, and clearly communicating that information to internal stakeholders—including clinical and operational staff and management—is important to ensure a consistent understanding of the boundaries of the regulatory relief. Contemporaneous documentation, where possible, of a provider’s election to operate under waivers, or to take steps that may be at the outer reaches of what waivers permit, may be of assistance after the pandemic subsides, should an outside agency retrospectively review the provider’s operations. Providers and suppliers must also continue to ensure regulatory compliance with state law requirements.

    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Monica Wallace

    Partner

    Chicago

    More insights

  • CMS Updates COVID-19 Infection Control Guidance for Inpatient Hospital Settings

    CMS Updates COVID-19 Infection Control Guidance for Inpatient Hospital Settings

    ARTICLE / CLIENT ALERT

    CMS Updates COVID-19 Infection Control Guidance for Inpatient Hospital Settings

    March 31, 2020

    Read time: 7 min

    Key takeaways
    Overview

    On March 30, 2020, CMS issued updates to its prior QSO memorandum, expanding its infection control and prevention guidance to include hospitals, critical access hospitals and psychiatric hospitals. The updated QSO memorandum also adds expanded guidance with respect to visitors and transmission mitigation strategies.

    In depth

    Summary

    On March 30, 2020, the Centers for Medicare and Medicaid Services (CMS) updated a Quality, Safety & Oversight (QSO) memorandum addressed to state survey agencies to expand infection control and prevention guidance related to the Coronavirus (COVID-19) crisis. The updated QSO memorandum now applies to hospitals, critical access hospitals (CAHs) and psychiatric hospitals and provides expanded guidance related to visitors and transmission mitigation strategies.

    In Depth

    On March 30, 2020, CMS updated a Quality, Safety & Oversight (QSO) memorandum  (QSO-20-13-Hospitals-CAHs REVISED) addressed to state survey agencies identifying modifications to the survey and certification process in response to the growing COVID-19 crisis in the United States. While the original memorandum issued on March 4, 2020, focused on acute care hospitals and provided detailed guidance on screening visitors and patients, and monitoring and restricting healthcare facility staff from working in case of exposure, revisions to the QSO memorandum make clear that it also applies to psychiatric and critical access hospitals.

    The updated QSO memorandum addresses questions received by CMS from stakeholders and provides guidance to hospitals, psychiatric hospitals and critical access hospitals to address the COVID-19 pandemic and to provide guidance regarding infection control, visitation and patient placement. Key features of QSO-20-13-Hospitals-CAHs REVISED are described below.

    Section 1135 Waivers

    As has been discussed previously, CMS has waived numerous requirements applicable to all inpatient facilities. Such waivers were further expanded on March 30, 2020. If these waivers do not cover a particular need, facilities may email a request to 1135waiver@cms.hhs.gov, and the request will be reviewed on a case-by-case basis. Hospitals seeking up-to-date information and resources should contact their local health department if they have questions about patients or healthcare providers with suspected COVID-19 infections.

    Visitor Screening and Limitation of Visitors

    CMS recommends hospitals, psychiatric hospitals and CAHs screen all visitors and patients before or immediately upon arrival at the facility. All visitors and patients should be asked about the following:

    • Signs or symptoms of a respiratory infection, such as a fever, cough or difficulty breathing
    • Contact with a person who is positive for COVID-19, considered to be under investigation for COVID-19 or is ill with respiratory illness
    • Travel within the last 14 days to areas with widespread or ongoing COVID-19 community spread
    • Residence or working in a community where community-based spread of COVID-19 is occurring
    • International travel within the last 14 days to CDC Level 3 risk countries
    • Recent trips (within the last 30 days) on cruise ships.

    The QSO memorandum provides that hospitals should set limitations on visitation and either establish limited entry points for all visitors or establish alternative sites for screening before visitors are allowed to enter the facility. Suggested limitations on visitation include restricting the number of visitors per patient, limiting visitors to those that provide assistance to patients or permitting only those visitors under a certain age. Hospitals should provide signage at screening points and screening should include temperature checks or questions about fever. Visitors with symptoms of COVID-19 who are not seeking treatment should not be permitted to enter hospitals.

    While limits on visitation should be set, CMS cautions that patients must have adequate access to chaplains or clergy, in accordance with the Religious Freedom Restoration Act and Religious Land Use and Institutionalized Persons Act.

    With respect to organ procurement, CMS asks that donor hospitals continue to permit organ procurement coordinators into hospitals to discuss organ donation with families. CMS reiterated the critical nature of ensuring continued access to donated organs.

    Staff Returning to Work

    Current CDC guidance has two pathways for determining when healthcare staff who are exposed or infected with COVID-19 can return to work. If testing is available, staff should be excluded from work until their fever has resolved without medication, respiratory symptoms have improved, and two consecutive negative tests from nasopharyngeal swab specimens collected more than 24 hours apart have been produced. If no testing is available, staff should be excluded from work until three days after fever and respiratory symptoms have resolved without medications and at least seven days have elapsed since symptoms first appeared. Staff should also consult with the facility’s occupational health program for continued monitoring and should seek a re-evaluation if symptoms re-emerge or worsen.

    Mitigating Transmission

    Inpatient hospitals are encouraged to implement several steps to mitigate the transmission of COVID-19. These include, to the extent practicable:

    • Rescheduling elective surgeries, procedures, and non-critical visits.
    • Shifting elective urgent inpatient diagnostic and surgical procedures to outpatient settings.
    • Practicing social distancing of at least six feet in care settings.
    • Limiting visitors if a patient is positive for COVID-19 or meets the persons under investigation criteria.
    • Planning for a surge of critically ill patients and identifying ancillary spaces to care for such patients. This may include separate and alternate space in emergency departments, intensive care units or other patient care areas where COVID-19 patients may be cohorted away from other patients. Facilities should also consider identifying dedicated staff to care for COVID-19 patients.

    Admission Exceptions

    CMS authorizes hospitals to engage in several temporary solutions to expand bed capacity, many of which contemplate the Section 1135 waivers referenced in the QSO memorandum. These include:

    • Providing overflow care in excluded distinct part psychiatric units.
    • Relocating acute care inpatients to excluded distinct part inpatient rehabilitation units appropriate for the patient’s care needs in order to provide overflow care due to COVID-19 surge.
    • Relocating and admitting inpatients of an excluded rehabilitation unit to an acute care inpatient unit to provide care for overflow due to COVID-19 patients. For this waiver to be used, the inpatient facility’s acute care beds must be appropriate for providing care to rehabilitation patients and such patients must continue receiving intensive rehabilitation services.
    • Admitting excluded unit psychiatric inpatients to an acute care inpatient unit to expand bed capacity. In this situation, the acute care beds must be appropriate for psychiatric patients and the staff and environment are appropriate for providing safe care.

    Considerations for Patient Discharge

    With the expansion of the QSO memorandum to psychiatric hospitals, CMS notes special considerations may apply when discharging a patient with psychiatric or cognitive disabilities. When a patient diagnosed with COVID-19 is being discharged from a hospital, hospitals should pay special consideration to patients with psychiatric or cognitive disabilities to ensure the patients are able to adhere to COVID-19 discharge recommendations. This includes ensuring that patients comprehend the significance of isolation recommendations and the potential risk to household members. Alternatively, hospitals must ensure there is a family member or significant other to ensure the patient can comply with infection prevention and isolation recommendations.

    Key Takeaways

    CMS highlights the availability of Section 1135 waivers for hospitals and expanded the options available for hospitals to increase their bed capacity. CMS provides additional strategies to prevent the spread of COVID-19 in inpatient settings and provides guidance regarding healthcare workers returning to work after COVID-19 exposure or infection to mitigate potential healthcare worker shortages in light of community spread.

    Finally, CMS expands prior guidance to hospitals regarding restricting visitation in light of infection control concerns. The QSO memorandum applies to CAHs and psychiatric hospitals, as well as general acute care hospitals, emphasizing that screening should be provided to visitors and patients to the hospital. The QSO memorandum also provides a number of suggestions for screening visitors and strategies to prevent the spread of COVID-19.

    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    Caroline Reignley

    Partner

    Washington, DC

    More insights

  • CMS Updates Infection Control Guidance with Focus on Dialysis Facilities

    ARTICLE / CLIENT ALERT

    CMS Updates Infection Control Guidance with Focus on Dialysis Facilities

    March 31, 2020

    Read time: 5 min

    Key takeaways
    Overview

    On March 30, 2020, CMS issued updates to its March 9, 2020, memo from the Quality Safety and Oversight (QSO) Group on controlling and preventing the spread of Coronavirus (COVID-19) in dialysis facilities and other facilities. (See our original On the Subject here.) Below is a summary of the noteworthy additions to the updated memo, which focus on dialysis facilities and services.

    In depth

    Dialysis Facilities

    The March 30, 2020, dialysis facility QSO memo (QSO022019-ESRD Revised) focuses on several practices to limit the transmission of COVID-19 in dialysis facility settings through screening patients and staff, isolating patients with suspected or confirmed COVID-19 infections, and transferring patients to alternative dialysis locations. The memo also addresses specific practices applicable to special purpose renal dialysis facilities (SPRDFs).

    Identifying Risk of COVID-19 in Patients and Staff

    Dialysis facilities are encouraged to screen all patients, staff and visitors for COVID-19 symptoms using the four criteria listed our prior On the Subject. Patients who present with signs and symptoms of respiratory infections should be identified prior to entering the dialysis treatment area and should be required to wear a face mask at check-in and until they leave the facility. Dialysis facilities are also encouraged to post signage at the facility entrance instructing patients to notify staff if they have a fever or respiratory infection symptoms so that appropriate precautions may be exercised. Staff who demonstrate signs and symptoms of respiratory infection should not report to work, or if symptoms arise at work, they should immediately stop working, don a face mask, self-quarantine at home, and inform the dialysis facility administrator of any patients or staff with whom they came into contact.

    Caring for Patients with COVID-19 Symptoms

    CMS recognizes that patients will continue to need dialysis treatment during the symptomatic stage of a COVID-19 infection, so dialysis facilities are encouraged to provide masks to symptomatic patients and to have space in waiting areas to segregate ill patients from other patients by at least six feet. If possible, dialysis treatment of symptomatic patients should occur in a separate room with the door closed or otherwise away from the main flow of traffic, and at least six feet from other patient stations. Medically stable patients who do not have other care needs could be asked to wait outside the facility until staff call the patient on their cell phone.

    Facilities should continue to follow infection control requirements, including hand hygiene, PPE, isolation, routine cleaning and disinfection procedures. For patients who receive at-home dialysis treatments, CMS emphasizes that monthly monitoring in onsite locations should continue in accordance with these precautions. If a dialysis facility anticipates having any PPE shortages, the facility should communicate with their state and local public health officials.

    Transferring Patients to Alternative Sites

    Dialysis facilities should consider transferring patients to another treatment site if the facility cannot fully implement the recommended precautions or if the patient requires care that the facility is unable to provide. Transport personnel and the receiving facility should be notified in advance of the patient’s healthcare needs, and the patient should wear a face mask and remain separated from other patients while awaiting transfer.

    Special Purpose Renal Dialysis Facilities (SPRDFs)

    Dialysis facilities may apply for SPRDF certification to serve dialysis patients in a temporary location, including hospitals and long-term care facilities, under emergency circumstances if COVID-19 presents an access-to-care issue such that patients would otherwise be unable to obtain treatment in the geographic service area. (42 CFR § 494.120; State Operations Manual Chapter 2, Section 2272). SPRDF certification may also be requested for situations where a dialysis facility encounters symptomatic patients whom it must cohort in order to limit and contain exposure.

    SPRDF certifications are effective for eight months in any 12-month period. Once the SPRDF certification expires, facilities must have a plan for the safe and coordinated transfer of its patient(s) to a permanent outpatient dialysis setting. To participate in bill Medicare, the SPRDF must complete and submit a Medicare enrollment application; complete and submit an end-stage renal disease certification application; obtain any applicable state requirements (e.g., licensure, certificate of need); and undergo a federal survey (although services may be provided before the survey is completed). SPRDF certifications do not require a Section 1135 waiver.

    Key Takeaways: Dialysis services remain necessary for patients infected with COVID-19 or demonstrating signs and symptoms of respiratory infections. Dialysis facilities are advised to provide masks and segregate symptomatic patients by at least six feet if a private room or separate wing is not available. A dialysis facility may enroll in Medicare and be certified as a special purpose renal dialysis facility for up to eight months in emergency situations such as the current public health crisis with the spread of COVID-19.

    Authors
    More insights

  • CMS Issues Additional Guidance on EMTALA Requirements for Hospitals

    ARTICLE / CLIENT ALERT

    CMS Issues Additional Guidance on EMTALA Requirements for Hospitals

    March 31, 2020

    Read time: 2 min

    Key takeaways
    Overview

    On March 30, 2020, CMS issued QSO-20-15-REVISED, which updated and expanded the guidance provided in its original QSO-20-15 memorandum issued March 9, 2020, as further described in the On the Subject appended below. QSO-20-15-REVISED addresses a number of key issues related to the Emergency Medical Treatment and Labor Act (EMTALA) as applied to hospitals in light of the COVID-19 pandemic, and provides guidance for hospitals struggling to maintain compliance and keep pace with increased patient volumes in the emergency department.

    In depth
    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    More insights

  • CMS Issues COVID-19 Infection Control Guidance for Certain Outpatient Settings

    CMS Issues COVID-19 Infection Control Guidance for Certain Outpatient Settings

    ARTICLE / CLIENT ALERT

    CMS Issues COVID-19 Infection Control Guidance for Certain Outpatient Settings

    March 31, 2020

    Read time: 6 min

    Key takeaways
    Overview

    On March 30, 2020, the Centers for Medicare and Medicaid Services (CMS) released a Quality, Safety & Oversight Group (QSO) memorandum (QSO-20-22-ASC, CORF, CMHC, OPT, RHC/FQHCs) addressing standards for infection control and prevention of Coronavirus (COVID-19) in certain outpatient care facilities, including ambulatory surgery centers (ASCs), community mental health centers (CMHCs), comprehensive outpatient rehabilitation facilities (CORFs), outpatient physical therapy or speech pathology services (OPTs), rural health clinics (RHCs) and federally qualified health centers (FQHCs).

    In depth

    The QSO memo addresses questions received by CMS from stakeholders and provides guidance to outpatient care settings other than hospital outpatient departments to address the COVID-19 pandemic and to provide guidance in reducing the likelihood of transmitting COVID-19 to other individuals.

    Temporary Closures

    Following up on its prior recommendation, CMS re-emphasizes the importance for all providers to delay non-essential medical, surgical and dental procedures to preserve personal protective equipment (PPE). Although CMS stops short of issuing an edict, CMS supplements its message by encouraging outpatient facilities to communicate with state and local health departments to reallocate PPE, bed capacity and ventilators to address community shortages.

    CMS also reminds outpatient facilities that the Medicare Conditions of Participation do not require such facilities to provide 24-hour care. Therefore, if it is in a facility’s and patients’ best interest to cancel an appointment and to close operations temporarily, that practice may be acceptable. Facilities should follow their emergency preparedness policies and procedures to determine when a temporary shutdown is appropriate and to ensure patients are properly notified. This temporary shutdown would not be considered voluntary termination of the facility’s Medicare agreement under 42 CFR § 489.52 or § 416.35(a)(3), and CMS will not take any administrative action as long as the facility resumes operations or voluntarily terminates its Medicare enrollment within 30 days after the public health emergency is lifted.

    To the extent practicable, facilities should announce their temporary closure on public-facing websites and social media platforms in addition to posting signs on entrance doors. Facilities that close temporarily are encouraged to contact local health officials to share ventilators and PPE if possible.

    Patient Screening

    CMS advises facilities to identify patients at risk for having COVID-19 infection before or immediately upon arrival at the facility by screening individuals for fever or other COVID-19 symptoms, recent travel to a country with restrictions on entry to the United States, contact with a person with known or suspected COVID-19, or residing in a community where community-based spread of COVID-19 is occurring. CMS further encourages outpatient facilities to ask patients to call ahead to report fever or respiratory symptoms so they can be triaged to a hospital setting. If circumstances permit, outpatient care providers should contact patients shortly before their appointments to reconfirm the absence of fever or respiratory symptoms.

    If space restrictions allow, outpatient care providers should establish limited entry points for all patients and should consider establishing alternative entry points for screening patients before entry. Any individual who demonstrates symptoms should be given a face mask at check-in and told to wear it for the duration of their visit. Outpatient care facilities should post signs at entrances with instructions in all appropriate languages advising patients to contact a staff member about any fever or respiratory symptoms that they are experiencing.

    Visitation

    Outpatient facilities do not have the same frequency of visitors as may be seen in other care settings; however, CMS recommends that outpatient care facilities communicate with patients about any changes to policies and procedures regarding appointments and any visitor restrictions. CMS also encourages outpatient facilities to implement for visitors the same screening restrictions in place for patients and to restrict visitation rights to symptomatic visitors. Facilities should also consider setting limitations on visitation depending on the type of care provided. For some facilities, this may mean a restriction on the number of visitors. For other facilities this may mean restricting visitors only to those who provide assistance, are participating in joint therapy or are under a certain age.

    Staff Screening and Access to PPE

    Outpatient facilities should implement the same screening practices for staff as have been implemented for patients. Any staff that demonstrate symptoms while on the job should immediately stop work, don a facemask, self-isolate at home and inform the appropriate persons, including the local health department, about individuals, equipment and locations that the staff member contacted. Staff with confirmed or suspected COVID-19 should be restricted from returning to work based onguidelines from the Centers for Disease Control and Prevention (CDC). (See also https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html for risk assessments applicable to healthcare workers exposed to COVID-19 infected patients)) Furthermore, outpatient facilities should be diligent while cleaning and disinfecting surfaces; however, they should be equally diligent about providing staff with sufficient PPE to prevent exposure to infectious agents or chemicals.

    Outpatient facilities are encouraged to have sufficient stock of supplies necessary to ensure hand and respiratory hygiene and cough etiquette for patients, visitors and staff, including no-touch trash receptacles, tissues and alcohol-based hand sanitizer. In addition to supplies for hygiene, CMS reiterated that outpatient facilities must maintain adequate supplies and equipment required by patients’ individualized plans of care. Given supply shortages, however, CMS will not cite facilities for having inadequate supplies for reasons outside of their control. In such an event, facilities should take action to mitigate any shortages and demonstrate that they are taking all reasonable steps to obtain necessary supplies.

    Facilities are also instructed to notify local and state health departments regarding shortages of supplies and to follow national guidelines for optimizing their current supplies and/or to implement safe alternatives for patient care. Outpatient care facilities may be cited for not having or providing necessary supplies for reasons that they could control or for hoarding supplies in violation of President Trump’s March 23, 2020, Executive Order.

    Key Takeaways: Outpatient facilities are encouraged to delay non-essential procedures and to share stores of PPE and ventilators with other front-line COVID-19 care providers to the extent practicable. If outpatient facilities decide to cease operations temporarily, CMS will not consider that cessation to constitute voluntary termination of the facility’s Medicare agreement as long as operations resume within 30 days after the public health emergency declaration is lifted. If outpatient facilities continue operations during the COVID-19 crisis, they should screen patients and staff for infections, revise their policies to reduce visitation practices and use best efforts to ensure ample access to PPE.

    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    More insights

  • Amending Your Credit Agreement in the Era of COVID-19

    Amending Your Credit Agreement in the Era of COVID-19

    ARTICLE / CLIENT ALERT

    Amending Your Credit Agreement in the Era of COVID-19

    March 31, 2020

    Read time: 5 min

    Key takeaways
    Overview

    In this unprecedented time, private equity sponsors and their portfolio companies and other corporate borrowers are concerned about access to liquidity as well as compliance with payment and other obligations under their credit documents. The chart included in this article outlines borrower-friendly amendments that should be considered by borrowers to stay afloat until the economy gets up and running again.

    In depth

    In this unprecedented time, private equity sponsors and their portfolio companies and other corporate borrowers are concerned about access to liquidity as well as compliance with payment and other obligations under their credit documents.

    We have recently seen various government regulators focused on ensuring that financial institutions work with issuers. For example, the Executive Order 202.9, issued by New York State Governor Andrew M. Cuomo on Saturday, March 21, 2020, declares it an “unsafe and unsound business practice” if a bank does not grant a forbearance to a business that has a financial hardship as a result of the COVID-19 pandemic. The Interagency Statement on Loan Modifications and Reporting for Financial Institutions Working with Customers Affected by the Coronavirus, issued by the board of governors of the Federal Reserve System, the Federal Deposit Insurance Corporation, the National Credit Union Administration, the Office of the Comptroller of the Currency, the Consumer Financial Protection Bureau and the State Banking Regulators encourages financial institutions to “work prudently with borrowers who are or may be unable to meet their contractual payment obligations because of the effects of COVID-19.”

    While these statements and orders may not be binding, they are instructive as to the current environment in which we expect lenders will appreciate the financial peril facing their borrowers and the need to work together to formulate creative and collaborative solutions to ensure their financing arrangements do not present an impediment to recovery.

    The subsequent chart outlines borrower-friendly amendments that should be considered by borrowers to stay afloat until the economy gets up and running again:

     

    Debt Financing Credit Agreement Amendment Considerations

     

    Preserving Liquidity
    • Defer interest payments or interest being paid-in-kind, in each case, until a specified date.
    • Defer principal amortization payments or principal being paid-in-kind, in each case, until a specified date.
    • Consider deferring 2020 administrative agency and collateral agency fees and other fees on a deal-by-deal basis.
    • Waive or defer 2019 and 2020 Excess Cash Flow mandatory pre-payments.
    • Consider waiving or deferring other mandatory pre-payments on a deal-by-deal basis.
    • Consider modifications to disposition of assets provisions to permit, as applicable, (a) licensing intellectual property, (b) selling unused or obsolete inventory, (c) factoring receivables or other assets, and (d) accelerating settlements related to third-party claims.
    • Remove some restrictions around equity cures, such as allowing cures during the fiscal quarter and allowing for cures beyond the amount necessary to comply with financial covenants.
    • Exclude the impact of COVID-19 from the Material Adverse Effect definition so it is no longer a concern when bringing down representations in borrowing notices.
    • Consider building in the ability to participate in applicable government bailout programs such as SBA loans.
    Financial Covenant Compliance
    • Reset financial covenant holidays or financial covenant levels, in each case, until a specified date.
    • Addition of EBITDA add-back for fees, costs, losses, charges, expenses and lost profits and revenues in connection with any natural disaster, pandemic, epidemic, disease outbreak or other public health emergency (including the Coronavirus Disease 2019 (COVID-19) or any similar or related disease caused by the SARS-CoV-2 virus), including any such items related to sourcing new supply chains.
    • Consider modifications to relevant Consolidated Net Income adjustments and/or EBITDA add-backs, as applicable: (a) extraordinary, unusual, one-time or non-recurring fees, costs, losses, charges and expenses, (b) fees, costs, losses, charges and expenses relating to facility or operational shutdowns, (c) business interruption and other insurance proceeds, (d) reimbursable or indemnifiable costs, losses, charges and expenses, (e) restructuring fees, costs, losses, charges and expenses, (f) cost-savings initiatives, (g) goodwill impairment and (h) lost profits and revenues.
    Financial Reporting Requirements
    • Extend deadline for delivery of 2019 and 2020 audited financial statements (and related compliance certificates on a deal-by-deal basis) and, if necessary, revise credit agreement to permit a going concern qualification relating to COVID-19 effects.
    • Extend deadline for delivery of 2020 quarterly and/or monthly unaudited financial statements (and related compliance certificates on a deal-by-deal basis).
    Events of Default
    • Waive default interest or convert default interest to be paid-in-kind.
    • Waive the cross-defaults to certain indebtedness, if applicable, or material agreements.
    • Review all Events of Default to determine whether any other default waivers are needed.
    Eligible Assignees; Loan Assignments and Participations
    • Prevent lenders from assigning or participating the loans (including to a “Disqualified Institution”) without the borrower’s prior written consent.
    • If not already included, amend credit agreement to provide the ability for private equity sponsors to purchase the loans subject to customary caps and voting limitations.
    ABL Facility Considerations
    • Reduce excess availability or liquidity triggers due to greater-than-expected cash outlays due to COVID-19 expenditures.
    Authors

    Stephanie S. McCann

    Partner

    Chicago

    Joshua Samis

    Partner

    Chicago

    Gary B. Rosenbaum

    Partner

    Los Angeles

    More insights

  • COVID-19 Impact on Class Action Litigation

    COVID-19 Impact on Class Action Litigation

    ARTICLE / CLIENT ALERT

    COVID-19 Impact on Class Action Litigation

    March 31, 2020

    Read time: 7 min

    Key takeaways
    Overview

    The Coronavirus (COVID-19) pandemic creates unprecedented risk for class action exposure for companies. This article identifies the first wave of class actions we anticipate arising out of the COVID-19 pandemic.

    In depth

    The COVID-19 pandemic has already sparked a flurry of litigation activity. Parties and courts are feeling the immediate impact of the virus in the form of extensive postponements of trials and other court deadlines. With the spate of business closures, layoffs, financial losses, physical injuries and event cancellations, class action filings are likely to rise swiftly in the coming months. In fact, opportunistic class action litigators are already targeting companies for lawsuits relating to COVID-19.

    Class Actions Against Financial Institutions and Debt Collectors

    We anticipate heightened risk of class actions against debt collectors and servicers, as well as against banks to prevent foreclosure proceedings. Many states are suspending private companies’ ability to collect debts. One such action to prevent foreclosures was filed against Bank of America. (See James L. Shuff, et al. v. Bank of America, et al., Case No. 5:20-cv-00184, in the US District Court for the Southern District of West Virginia).

    Plaintiffs also filed a putative class action against Northstar Education Finance Inc., d/b/a Total Higher Education, related to the student loan provider’s suspension of an interest-rate reducing benefit program during the COVID-19 pandemic. The complaint, filed in federal court in Minnesota, alleges that the defendant unlawfully suspended a repayment bonus program citing “changes in economic conditions.” (See Oksenendler v. Northstar Education Finance, Inc., Case No. 20-cv-00805, Dkt. No. 1, ¶ 5, March 26, 2020). Plaintiffs allege violation of loan agreements, a previous settlement agreement, and deceptive business practices because the suspension of the repayment bonus allegedly increased the interest rates on the plaintiff-borrowers’ loans.

    Class Actions Against Manufacturers and Retailers of Hand Sanitizers, Disinfectants and Protective Gear

    We anticipate class action litigation alleging that manufacturers and retailers of hand sanitizers, disinfectants and protective gear misrepresented the products’ level of protection against various viruses and bacteria. Similarly, class action lawsuits likely will be filed alleging that products did not keep users safe. These would include product liability class actions by healthcare workers (or consumers) against manufacturers of personal protective equipment (PPE), such as protective gowns, gloves and N95 masks.

    Consumers filed one of these class actions against Germ-X. (See David et al. v. Vi-Jon Inc., Case No. 20-cv-424, complaint filed, 2020 WL 1082551 (S.D. Cal. Mar. 5, 2020). The plaintiffs asserted claims against Germ-X for false advertising and violations of other laws for allegedly making false statements about Germ-X’s effectiveness against influenza and COVID-19. Similar suits were filed against the manufacturer of Purell (Gonzalez v. Gojo Indus. Inc., Case No. 20-cv-888, complaint filed, 2020 WL 560911 (S.D.N.Y. Feb. 1, 2020)) and Target (Taslakian, v. Target Corporation, et al., Case No. 20-cv-02667, complaint filed, 2020 WL 1367461 (C.D.Cal., March 20, 2020)).

    Class Actions Against Employers

    We expect a huge surge in class action litigation surrounding adverse employment actions due to the COVID-19 pandemic. Two recent examples were class actions filed in the Superior Court of California, County of San Francisco, against Uber and Lyft. The two cases, Verhines v. Uber Technologies, Inc., and Rogers v. Lyft, Inc., seek injunctions declaring that rideshare drivers are employees under California Assembly Bill 5 such that the drivers can be eligible for state-mandated sick pay. The firm bringing the actions, Lichten & Liss-Riordan, P.C., stated that it planned to bring similar actions in Massachusetts.

    We also expect class actions to be filed against employers arising out of layoffs, furloughs, medical leaves and other business interruptions. Another potential set of claims could be brought by employees for the alleged failure to keep workplaces safe from the pandemic.

    Securities Class Actions Against Issuers

    We anticipate increased securities class actions based on companies’ disclosures and responses to the COVID-19 pandemic. Some such cases are already being filed as the stock market continues to drop. Plaintiffs filed at least two such cases recently: one against Norwegian Cruise Lines and one against biotech company Inovio. The Norwegian Cruise Lines case asserts that the defendant provided customers with false assurances of safety relating to COVID-19. (See Douglas v. Norwegian Cruise Lines, Case No. 20-cv-21107, complaint filed, 2020 WL 1226410 (S.D. Fla. Mar. 12, 2020)).

    The Inovio case alleges that Inovio’s CEO made false or misleading statements about a potential vaccine for COVID-19. (See McDermid v. InovioPharm. Inc., Case No. 20-cv-1402, complaint filed, 2020 WL 1227260 (E.D. Pa. Mar. 12, 2020)). We anticipate additional class action litigation related to new vaccines or other drugs purporting to cure or treat COVID-19.

    We also anticipate similar claims by ESOP investors.

    Class Actions Against Retailers for Price Gouging

    We anticipate that class action lawsuits accusing retailers of price gouging will increase as a result of the COVID-19 pandemic. Price increases on toilet paper, hand sanitizers, protective masks and other essential products could create substantial risk for retailers. One such class action was filed against Amazon shortly after the Coronavirus outbreak. (See Armas v. Amazon.com Inc., Case No. 104631782, in the Eleventh Circuit Court in and for Miami-Dade County, Florida (alleging price gouging related to toilet paper and hand sanitizer)).

    Class Actions Against Travel Agencies, Ticket Brokers, Subscription Service Providers and Entertainment Venues for Travel and Event Cancellations

    We anticipate class actions against vacation real estate brokers because rental property owners fail to provide refunds of booking or service fees to guests who cannot travel due to the pandemic. Additionally, we expect plaintiffs to target event ticket aggregators for cancelled concerts and other live entertainment related to COVID-19. Moreover, subscription services for live events (such as streaming of live sports or events) could result in class action exposure. Season ticket holders for sporting events could form putative classes for cancelled games or whole seasons. Colleges and universities are now being sued for failure to provide tuition or room and board reimbursement to students. (See Rosenkrantz et al v. Arizona Board of Regents, Case No. 2:20-cv-00613-JZB in the U.S. District Court of the District of Arizona.)

    Similar cases could be brought against cruise lines, airlines, hotels and other travel companies for allegedly failing to create a safe environment or for alleged damages relating to delays or cancellations.

    Class Actions Against Insurers

    The pandemic heightens class action exposure for insurers, including travel insurance and business interruption insurance, for denial of claims based on force majeure or other contractual clauses. Manufacturers, distributors and retailers are facing business disruption as companies in the supply chain are unable to provide goods. They will certainly be reviewing their policies for some relief.

    Potential class claims could also be brought by providers or subscribers against health insurers for denials of coverage for new vaccines and treatments for COVID-19 as experimental and investigative or not medically necessary.

    Class Actions Against Healthcare Providers

    Class claims likely will be brought by residents (or heirs of deceased residents) of nursing homes for negligent management of the COVID-19 pandemic. Hospitals and other providers of healthcare could get named in similar lawsuits.

    * * * * *

    COVID-19 is causing unprecedented disruption and injuries to our communities. A significant risk to businesses is responding to a wave of class actions that may be filed relating to the pandemic. McDermott is well positioned to give strategic advice to clients to try to avoid these lawsuits and to defend them once filed. For an in-depth discussion of any given issue or for customized preventative measures, contact the authors or your McDermott attorney contact for full access to McDermott’s capabilities.

    Authors

    Daniel Campbell

    Partner

    Chicago

    More insights

  • COVID-19 – How Finance Contracts in Germany Have Been Affected

    ARTICLE / CLIENT ALERT

    COVID-19 – How Finance Contracts in Germany Have Been Affected

    March 31, 2020

    Read time: 2 min

    Key takeaways
    Overview

    The spread of the COVID-19 pandemic and its consequences have affected existing financing contracts in a variety of ways. Various industrial sectors are experiencing a loss in sales and therefore there is a need to adjust existing credit contract commitments.

    Read the full article in German here.

    In depth
    Authors
    More insights